Compare Stocks → Uncover this 2024 Hidden Gem (From Tips4Traders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BLUNASDAQ:LABPNASDAQ:NEXINASDAQ:SNSE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUBELLUS Health$14.74$14.62$6.38▼$14.76$1.87B0.193.08 million shs3.45 million shsLABPLandos Biopharma$21.76+0.4%$12.06$2.50▼$21.87$67.83M0.1422,634 shs20,783 shsNEXINexImmune$3.29+4.4%$6.00$1.25▼$28.69$3.49M1.841.85 million shs6,901 shsSNSESensei Biotherapeutics$0.98-2.0%$0.95$0.51▼$1.93$24.64M0.1765,355 shs31,548 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUBELLUS Health0.00%0.00%0.00%0.00%+2.08%LABPLandos Biopharma+0.74%+0.53%+226.36%+356.21%+621.37%NEXINexImmune-9.22%-20.35%-43.75%-62.37%-68.89%SNSESensei Biotherapeutics+1.20%-9.09%-5.21%+26.41%-39.76%AI “wealth window” is closing soon! (Ad)Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLUBELLUS Health0.0656 of 5 stars1.00.00.00.00.63.30.0LABPLandos Biopharma0.3356 of 5 stars1.03.00.00.03.00.80.6NEXINexImmuneN/AN/AN/AN/AN/AN/AN/AN/ASNSESensei Biotherapeutics3.9925 of 5 stars3.53.00.04.80.61.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUBELLUS Health2.00Hold$14.750.07% UpsideLABPLandos Biopharma2.00Hold$20.42-6.16% DownsideNEXINexImmuneN/AN/AN/AN/ASNSESensei Biotherapeutics3.00Buy$4.00306.96% UpsideCurrent Analyst RatingsLatest LABP, NEXI, BLU, and SNSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2024LABPLandos BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$50.00 ➝ $20.42(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUBELLUS Health$15K124,613.93N/AN/A$3.09 per share4.77LABPLandos Biopharma$18M3.77N/AN/A$10.20 per share2.13NEXINexImmuneN/AN/AN/AN/A$33.43 per shareN/ASNSESensei BiotherapeuticsN/AN/AN/AN/A$2.60 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUBELLUS Health-$76.08M-$0.72N/AN/AN/A-578,586.63%-24.27%-23.14%N/ALABPLandos Biopharma-$21.93M-$3.46N/AN/AN/AN/A-54.92%-49.09%5/10/2024 (Estimated)NEXINexImmune-$62.51M-$30.89N/A∞N/AN/A-216.33%-157.05%5/20/2024 (Estimated)SNSESensei Biotherapeutics-$34.10M-$1.22N/AN/AN/AN/A-44.01%-38.58%5/14/2024 (Estimated)Latest LABP, NEXI, BLU, and SNSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023LABPLandos Biopharma-$0.91-$0.99-$0.08-$0.99N/AN/A2/28/2024Q4 2023SNSESensei Biotherapeutics-$0.32-$0.30+$0.02-$0.30N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUBELLUS HealthN/AN/AN/AN/AN/ALABPLandos BiopharmaN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUBELLUS HealthN/A33.4233.42LABPLandos BiopharmaN/A6.096.09NEXINexImmuneN/A1.661.66SNSESensei Biotherapeutics0.0111.9211.92OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUBELLUS Health90.37%LABPLandos Biopharma49.06%NEXINexImmune9.85%SNSESensei Biotherapeutics10.50%Insider OwnershipCompanyInsider OwnershipBLUBELLUS Health24.17%LABPLandos Biopharma1.30%NEXINexImmune19.40%SNSESensei Biotherapeutics25.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBLUBELLUS Health74126.81 million96.16 millionNot OptionableLABPLandos Biopharma193.12 million3.08 millionNot OptionableNEXINexImmune221.06 million853,000Not OptionableSNSESensei Biotherapeutics2825.07 million18.68 millionNot OptionableLABP, NEXI, BLU, and SNSE HeadlinesSourceHeadlineSensei Biotherapeutics (NASDAQ:SNSE) Stock Price Down 1.8%americanbankingnews.com - April 12 at 2:02 AMSensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conferenceglobenewswire.com - April 9 at 7:30 AMSensei Biotherapeutics CFO Erin Colgan to resignuk.investing.com - April 4 at 11:42 PMSensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironmentglobenewswire.com - April 4 at 4:05 PMSensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposiumglobenewswire.com - March 22 at 7:30 AMSensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferencesglobenewswire.com - March 6 at 7:30 AMBuy Rating Affirmed for Sensei Biotherapeutics on Strong Fiscal Health and Promising Clinical Trialsmarkets.businessinsider.com - February 29 at 3:22 PMSensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlightsglobenewswire.com - February 28 at 7:30 AMSensei Biotherapeutics Announces Board Member Resignation and Consultant Rolemsn.com - February 9 at 10:35 AMSensei Biotherapeutics Streamlines Board, Appoints Interim Chairmsn.com - February 9 at 10:35 AMSensei Biotherapeutics to Present at Upcoming Conferencesfinance.yahoo.com - February 7 at 7:42 AMBuy Rating Affirmed for Sensei Biotherapeutics Amidst Promising SNS-101 Clinical Progress and Favorable Safety Datamarkets.businessinsider.com - January 6 at 1:14 AMSensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestonesfinance.yahoo.com - January 4 at 8:07 AMThe Potential Rise in the Price of Sensei Biotherapeutics Inc (SNSE) following insiders activityknoxdaily.com - January 1 at 9:39 AMAnalysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Praxis Precision Medicines (PRAX) and Sensei Biotherapeutics (SNSE)markets.businessinsider.com - December 4 at 10:40 PMHC Wainwright & Co. Initiates Coverage of Sensei Biotherapeutics (SNSE) with Buy Recommendationmsn.com - December 4 at 10:40 PMKeeping an Eye on Sensei Biotherapeutics Inc (SNSE) After Insider Trading Activityknoxdaily.com - November 7 at 2:19 PMSensei Biotherapeutics GAAP EPS of -$0.28 in-linemsn.com - November 7 at 9:19 AMSensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlightsfinance.yahoo.com - November 7 at 9:19 AMSensei Biotherapeutics Inc (SNSE) Reports Q3 2023 Financial Resultsfinance.yahoo.com - November 7 at 9:19 AMSensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meetingfinance.yahoo.com - November 3 at 8:51 PMSensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meetingfinance.yahoo.com - October 25 at 2:01 PMRockville cancer therapy firm Sensei Biotherapeutics faces delisting threat from Nasdaqbizjournals.com - October 24 at 2:01 PMSensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023finance.yahoo.com - October 23 at 8:01 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 High Short Interest Stocks Getting Squeezed With Upside To GoApril 5, 2024 9:25 AMView 5 High Short Interest Stocks Getting Squeezed With Upside To GoComprehensive PepsiCo Stock AnalysisApril 18, 2024 12:05 PMView Comprehensive PepsiCo Stock AnalysisAll Headlines Company DescriptionsBELLUS HealthNASDAQ:BLUBELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.Landos BiopharmaNASDAQ:LABPLandos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company has a strategic research collaboration with KU Leuven and University Hospitals Leuven to investigate the effects of NX-13 on epithelial cells with the inflammatory bowel disease. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.NexImmuneNASDAQ:NEXINexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.Sensei BiotherapeuticsNASDAQ:SNSESensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. Its Tumor Microenvironment Activated Biologics platform is designed to unleash the anti-tumor potential of T cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company's pipeline includes SNS-101, SNS-103, and SNS-102, monoclonal antibodies, which are in early development stages for the treatment of solid tumors. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.